this did not persist to 30-day mortality (28.8% vs 34.3%), 1-year survival (52.9% vs 46.7%), or overall mortality (32.7% vs 36.4%). There was also no difference in length of stay (8.4 days vs 9.0 days) or complications (54.9% vs 56.7%). Results are outlined in the Table . On multivariable analysis, leaving the operating room with an isolated type II endoleak did not significantly affect any operative or outcome variables. Specifically, the difference in mortality seen in the unadjusted model was lost on adjusted analysis.Conclusions: Isolated type II endoleaks seen at case completion for rEVAR are similarly benign to those seen at case completion for non-rEVAR. Isolated type II endoleaks in rEVAR do not significantly affect operative or outcome variables in adjusted models suggesting a "watch-and-wait" approach is acceptable.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.